Plasma proteomic and metabolomic characterization of COVID-19 survivors 6 months after discharge.

Coronavirus disease 2019 (COVID-19) has gained prominence as a global pandemic. Studies have suggested that systemic alterations persist in a considerable proportion of COVID-19 patients after hospital discharge. We used proteomic and metabolomic approaches to analyze plasma samples obtained from 30 healthy subjects and 54 COVID-19 survivors 6 months after discharge from the hospital, including 30 non-severe and 24 severe patients. Through this analysis, we identified 1019 proteins and 1091 metabolites. The differentially expressed proteins and metabolites were then subjected to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. Among the patients evaluated, 41% of COVID-19 survivors reported at least one clinical symptom and 26.5% showed lung imaging abnormalities at 6 months after discharge. Plasma proteomics and metabolomics analysis showed that COVID-19 survivors differed from healthy control subjects in terms of the extracellular matrix, immune response, and hemostasis pathways. COVID-19 survivors also exhibited abnormal lipid metabolism, disordered immune response, and changes in pulmonary fibrosis-related proteins. COVID-19 survivors show persistent proteomic and metabolomic abnormalities 6 months after discharge from the hospital. Hence, the recovery period for COVID-19 survivors may be longer.

Serum levels of laminin and von Willebrand factor in COVID-19 survivors 6 months after discharge.

OBJECTIVES: The aim of this study was to evaluate the clinical characteristics, pulmonary diffusion function, chest computed tomography (CT), and serum lung cell damage indicators of coronavirus disease 2019 (COVID-19) survivors 6 months after discharge. METHODS: Data of COVID-19 survivors discharged from hospital between January 21, 2020 and January 11, 2021 and healthy controls were collected. Serum levels of surfactant protein D (SP-D)1, the receptor for advanced glycation end products (RAGE)2, laminin, and von Willebrand factor (vWF) were measured in the healthy controls and COVID-19 survivors 6 months after discharge. The relationships between serum lung cell damage indicator levels and various parameters were explored. RESULTS: Fifty-two COVID-19 survivors (31 with non-severe disease and 21 with severe disease) and 30 controls were included. Serum levels of laminin in COVID-19 survivors 6 months after discharge were significantly higher than those in the controls. The increase was more significant in elderly and female patients. Serum levels of RAGE and vWF were not statistically different from those of the controls. However, 6 months after discharge, COVID-19 survivors with abnormal chest CT and those in the severe group had higher vWF levels. CONCLUSIONS: COVID-19 patients had abnormal lung injury indicators 6 months after discharge. The recovery time after infection is currently unknown, and long-term observation is required.

Detection and predictors of anti-SARS-CoV-2 antibody levels in COVID-19 patients at 8 months after symptom onset.

Aim: To determine SARS-CoV-2 specific IgM and IgG levels of patients with COVID-19 at 8 months after symptom onset and to explore the predictors of antibody levels. Materials & methods: The magnetic chemiluminescence method was used to measure the antibody levels. Clinical data were collected and analyzed retrospectively. Results: A total of 54 patients were enrolled in this study, of whom 59.3% were IgM positive and 96.4% were IgG positive. The multiple linear regression analysis revealed that the duration of RNA shedding, C-reactive protein level and disease severity were independent predictors of IgG levels. Conclusion: COVID-19 patients retained long-term viral-specific protective immunity. Disease severity, C-reactive protein level and duration of RNA shedding were related to antibody levels 8 months after symptom onset.

Kinetics of specific IgM and IgG antibodies in patients with COVID-19 in Tianjin

Objective: To dynamically detect and evaluate the serum specific levels of IgM and IgG and their variation patterns in critical and non-critical patients with COVID-19.

Clinical and diagnostic value of the combination of lymphocyte count and creatine kinase in the detection of coronavirus 2019.

The present study aimed to investigate the diagnostic efficiency of the absolute number of lymphocytes (LYM) and creatine kinase (CK) levels in the diagnosis of coronavirus disease 2019 (COVID-19). For this, the clinical data from 84 patients with COVID-19 admitted to Tianjin Haihe Hospital (Tianjin, China) between January and February 2020 were collected. The patients were divided into the following groups: The common COVID-19 group (n=61) and severe COVID-19 group (n=23). In addition, 30 healthy subjects were included as a control group. The results demonstrated that the percentage of neutrophils (NEU%) was significantly increased, while the absolute number of white blood cells, LYM and the percentage of lymphocytes (LYM%) were significantly decreased in patients with COVID-19. Furthermore, in the severe group, the absolute number of red blood cells in female patients, the NEU%, the neutrophil-to-lymphocyte ratio (NLR) and the serum levels of interleukin-6 and C-reactive protein (CRP) were markedly elevated, while those of LYM and LYM% were significantly decreased (all P<0.05). In addition, in the receiver operating characteristics curve analysis for the combination of LYM + CK, the area under the curve values were 0.96 and 1.00, with a sensitivity of 95.08 and 100%, specificity of 86.67 and 100% and cut-off values of 0.42 and 0.50 for the common and severe COVID-19 group, respectively. The results indicated that the diagnostic efficiency of LYM + CK was higher than that of each single factor. Finally, a moderate correlation of lactate dehydrogenase with CRP and NLR (r=0.492 and 0.433, respectively; both P<0.05) was obtained. Overall, the results of the present study indicated that the values of LYM and CK were associated with the progression of COVID-19, suggesting that the combination of both factors may be of clinical diagnostic value for COVID-19.

Analysis of clinical characteristics of patients with COVID-19 in Tianjin

Objective: To explore the epidemiological, clinical and imaging characteristics of patients with novel coronavirus disease 2019 (COVID-19) in Tianjin.

Preliminary Analysis of B- and T-Cell Responses to SARS-CoV-2.

BACKGROUND AND OBJECTIVE: Without a specific antiviral treatment or vaccine, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic, affecting over 200 countries worldwide. A better understanding of B- and T-cell immunity is critical to the diagnosis, treatment and prevention of coronavirus disease 2019 (COVID-19). METHODS: A cohort of 129 patients with COVID-19 and 20 suspected cases were enrolled in this study, and a lateral flow immunochromatographic assay (LFIA) and a magnetic chemiluminescence enzyme immunoassay (MCLIA) were evaluated for SARS-CoV-2 IgM/IgG detection. Additionally, 127 patients with COVID-19 were selected for the detection of IgM and IgG antibodies to SARS-CoV-2 to evaluate B-cell immunity, and peripheral blood lymphocyte subsets were quantified in 95 patients with COVID-19 to evaluate T-cell immunity. RESULTS: The sensitivity and specificity of LFIA-IgM/IgG and MCLIA-IgM/IgG assays for detecting SARS-CoV infection were > 90%, comparable with reverse transcription polymerase chain reaction detection. IgM antibody levels peaked on day 13 and began to fall on day 21, while IgG antibody levels peaked on day 17 and were maintained until tracking ended. Lymphocyte and subset enumeration suggested that lymphocytopenia occurred in patients with COVID-19. CONCLUSIONS: LFIA-IgM/IgG and MCLIA-IgM/IgG assays can indicate SARS-CoV-2 infection, which elicits an antibody response. Lymphocytopenia occurs in patients with COVID-19, which possibly weakens the T-cell response.